

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

LANSOPRAZOLE ENTERIC-COATED CAPSULES OBTAIN DRUG REGISTRATION APPROVAL

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Lansoprazole Enteric-coated Capsules (30mg) (the “**Product**”) developed by the Group have obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China.

The Product is a proton pump inhibitor that exerts gastric acid secretion inhibitory effects. Upon reaching the acid-secreting canaliculi of gastric mucosal parietal cells, the drug is converted into an active form under acidic conditions. This active substance binds to the sulfhydryl (-SH) groups of the proton pump (H^+/K^+ -ATPase) located in that region, inhibiting the enzyme’s activity and thereby effectively suppressing gastric acid secretion. The Product is indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, Zollinger-Ellison syndrome, and anastomotic ulcer. It is a commonly used proton pump inhibitor in clinical practice.

The approval of the Product will further enrich the Group’s product portfolio in the field of digestion and metabolism.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 26 May 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.